Page 101 - Genentech News Today

Patient preferences should be considered when selecting the optimal treatment regimen for patients with relapsed/refractory follicular lymphoma, as both CD19-directed CAR T-cell therapies and CD20-targeted bispecific antibodies can be efficacious in this population, according to a presentation by Caron A. Jacobson, MD, MMSc, at the 2023 SOHO Annual Meeting.

Antibody treatments may be able to activate the immune system to fight diseases like Parkinson’s, Alzheimer’s and colorectal cancer, but they are less effective when they bind with themselves and other molecules that aren’t markers of disease.

New PagerDuty Operations Cloud capabilities bridge the gap between customer service and technical teams for reducing costs and improving customer satisfaction ...

/PRNewswire/ -- The prominence of large language models (LLMs) has unleashed a wave of opportunity for enterprises to unlock new competitive advantages and...

/PRNewswire/ -- Today, the National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers—presented new recommendations for screening and...

Divarasib produced responses in patients with non-small cell lung cancer, colorectal cancer, and other solid tumors in a phase 1 trial.

Here are the speakers and sessions most highly anticipated by veteran DPE attendees.

This systematic review and dose-response meta-analysis evaluates the efficacy and tolerability of gefapixant, a new P2X3 antagonist, for the treatment of adults

This season’s vaccine is tailored to the SARS-CoV-2 XBB.1.5 sublineage and indicated as a single dose for most individuals 5 years of age and older Pre-clinical data show that the updated...

Lineage Cell Therapeutics, Inc. , a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today that Gary S. Hogge, D.V.M., M.S., Ph.D.,...